Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

Inclusion Criteria: * 1)Age 18-70 years old (both ends included), both male and female; * 2)At least one evaluable lesion, with previous biopsy or histopathological confirmation of high-grade glioma (WHO grade 3-4), and after comprehensive treatment, imaging examination indicates continued progression or recurrence; * 3\) The pathological tissues removed by surgery can be used for immunohistochemical detection of target proteins (paraffin sections should be within half a year), and the expression of B7-H3 is positive; * 4\) KPS ≥ 60 points; * 5)Expected survival \> 3 months; * 6)Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before receiving QH104 Cell Injection for the first time):White blood cell count (WBC) ≥ 3 x 10\^9/L;Lymphocyte count (LY) ≥ 0.8 x 10\^9/L;Hemoglobin (Hb) ≥ 90g/L;Platelet (PLT) ≥80×10\^9/L;Albumin transaminase (ALT) \& albumin transaminase (AST) \<1.5×ULN;Serum creatinine (Cr) \<1.5 x ULN;Total bilirubin \< 1.5 x ULN;PT \& PTT ≤ 1.25 x ULN. * 7)No obvious hereditary diseases; * 8)Normal cardiac function with cardiac ejection index \>55%; * 9)No bleeding and coagulation disorders; * 10)Women of childbearing age (15-49 years old) must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception during the clinical trial and for 3 months after the last cell infusion; * 11\) Sign the informed consent form. Exclusion Criteria: * 1)Pregnant and lactating women; * 2)Those with organ failure:Heart: Class III and IV;Liver: up to grade C of the Child-Turcotte Liver -Function Classification;Kidney: chronic kidney disease stage 4 or above; renal insufficiency stage III or above;Lungs: symptoms of severe respiratory failure with involvement of other organs;Brain: central nervous system abnormalities or impaired consciousness; * 3)patients with combined second tumors; * 4)patients with active hepatitis B or C virus, HIV infection, or other untreated active infection; * 5)any severe, uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis; * 6)Current systemic use of steroid cell (except for recent or current use of inhaled steroids) substances; * 7\) have a chronic disease requiring immunologic or hormonal therapy; * 8\) have an allergy to immunotherapy and related cells; * 9\) 10)Patients with a history of organ transplantation or who are awaiting organ transplantation; * 10)Participation in other clinical trials within the previous 30 days; * 11)Those who are not suitable for clinical trials for other reasons in the opinion of the investigator.